PSI Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

PSI Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13	Closed	-$3	–	959
2024 Q4	$3	Hold	13	–	–	﹤0.01%	889
2024 Q3	$28	Hold	13	–	–	﹤0.01%	884
2024 Q2	$67	Hold	13	–	–	﹤0.01%	856
2024 Q1	$70	Hold	13	–	–	﹤0.01%	790
2023 Q4	$101	Buy	+13	New	+$45	﹤0.01%	849

Other funds holding SYRS

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

1CM

1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

PSI Advisors's SYRS Position: Q1 2025 in Review

PSI Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 13 shares — an estimated $3 sold.

PSI Advisors first reported a position in SYRS in Q4 2023 and held it in 5 quarters. The position peaked at $101 in Q4 2023. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

PSI Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
PSI Advisors sold 13 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $3.
PSI Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2023 and held it in 5 quarters.
PSI Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $101 in Q4 2023.
7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on PSI Advisors's 13F filing for Q1 2025, filed 21 Apr 2025.